Radiopharmaceuticals for Molecular Imaging — MCQs
Which of the following statements best describes the mechanism of action of insulin on target cells?
Hot spot in heart is seen in which scan
Which of the following is used in the treatment of well-differentiated thyroid carcinoma?
Radiation-induced necrosis can be diagnosed by:
Which radioisotope is PRIMARILY used for detecting acute myocardial infarction rather than assessing myocardial perfusion?
Radiopharmaceutical used for phagocyte study scan:
Technetium-99m methylene diphosphonate is structurally similar to
A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?
In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?
A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?
Radiopharmaceuticals for Molecular Imaging Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following statements best describes the mechanism of action of insulin on target cells?
- A. Insulin binds to a receptor on the outer surface of the plasma membrane, activating adenylate cyclase through the Gs protein.
- B. Insulin binds to a cytoplasmic receptor and is transferred as a hormone receptor complex to the nucleus to modulate gene expression.
- C. Insulin enters the cell and causes the release of calcium ions from intracellular stores.
- D. Insulin binds to a transmembrane receptor on the outer surface of the plasma membrane, activating the tyrosine kinase in the cytosolic domain of the receptor. (Correct Answer)
Explanation: ***Insulin binds to a transmembrane receptor on the outer surface of the plasma membrane, activating the tyrosine kinase in the cytosolic domain of the receptor.*** - **Insulin** is a **peptide hormone** and cannot freely pass through the lipid bilayer, thus it binds to a **transmembrane receptor** on the cell surface. - This binding leads to the activation of the receptor's intrinsic **tyrosine kinase activity** in the intracellular domain, initiating a signaling cascade. *Insulin binds to a cytoplasmic receptor and is transferred as a hormone receptor complex to the nucleus to modulate gene expression.* - This mechanism describes the action of **steroid hormones**, which are lipid-soluble and can cross the cell membrane, binding to **intracellular receptors**. - **Insulin** acts via a **cell surface receptor** and its downstream effects are mediated through signal transduction pathways, not direct nuclear translocation. *Insulin binds to a receptor on the outer surface of the plasma membrane, activating adenylate cyclase through the Gs protein.* - This mechanism is characteristic of **G-protein coupled receptors (GPCRs)**, which activate or inhibit enzymes like adenylate cyclase via G-proteins to produce second messengers like cyclic AMP. - The **insulin receptor** is a **receptor tyrosine kinase**, not a GPCR, and does not directly activate adenylate cyclase via Gs protein. *Insulin enters the cell and causes the release of calcium ions from intracellular stores.* - While some hormones and neurotransmitters can trigger the release of intracellular **calcium ions**, this is typically mediated by specific pathways (e.g., GPCRs linked to phospholipase C). - **Insulin** does not directly enter target cells to cause calcium release; its actions are primarily mediated through receptor tyrosine kinase signaling pathways.
Question 2: Hot spot in heart is seen in which scan
- A. Thallium
- B. Gallium
- C. Albumin labelled
- D. Tc pyrophosphate scan (Correct Answer)
Explanation: ***Tc pyrophosphate scan*** - A **technetium-99m pyrophosphate (Tc-PYP) scan** demonstrates a "hot spot" in the heart in cases of **acute myocardial infarction** due to the tracer binding to calcium deposits in necrotic cardiomyocytes. - This hot spot indicates recent myocardial damage and is particularly useful in diagnosing **amyloidosis** (specifically transthyretin cardiac amyloidosis) where the tracer binds to amyloid fibrils. *Thallium* - **Thallium-201** is used in myocardial perfusion imaging to assess areas of reduced blood flow or infarction, creating a "cold spot" (decreased uptake). - It acts as a potassium analog and is taken up by viable myocardial cells, thus areas of ischemia or necrosis appear as defects rather than hot spots. *Gallium* - **Gallium-67** scans are primarily used to detect infection and inflammation, as well as certain tumors. - While it can accumulate in areas of inflammation in the heart (e.g., myocarditis), it does not create a characteristic "hot spot" associated with acute myocardial infarction. *Albumin labelled* - **Technetium-99m labeled albumin** (e.g., Technetium-99m macroaggregated albumin, MAA) is typically used for lung perfusion scans to diagnose pulmonary embolism or for gastrointestinal bleeding studies. - It is not used for direct assessment of myocardial damage or to create a "hot spot" in the heart for ischemic events.
Question 3: Which of the following is used in the treatment of well-differentiated thyroid carcinoma?
- A. I131 (Correct Answer)
- B. 99m Tc
- C. 32p
- D. MIBG
Explanation: ***I131*** - **Radioactive iodine (I131)** is specifically absorbed by **well-differentiated thyroid cancer cells** because these cells retain the ability to uptake iodine, unlike other types of cancer cells. - Used for **ablating residual thyroid tissue** after surgery and for treating **metastatic well-differentiated thyroid carcinoma** [1]. *99m Tc* - **Technetium-99m (99m Tc)** is primarily used for **diagnostic imaging** (e.g., thyroid scans, bone scans), not for therapeutic treatment of thyroid cancer. - It has a short half-life and emits gamma rays, making it suitable for imaging but generally not for delivering sustained radiation for therapeutic effect. *32p* - **Phosphorus-32 (32p)** is a beta-emitting radionuclide used in the treatment of certain hematological malignancies, such as **polycythemia vera**, and for palliative treatment of bone metastases. - It is not selectively taken up by thyroid cancer cells and therefore is not used in the treatment of thyroid carcinoma. *MIBG* - **Metaiodobenzylguanidine (MIBG)**, often labeled with I123 (diagnostic) or I131 (therapeutic), is used in the diagnosis and treatment of **neuroendocrine tumors** like **pheochromocytoma** and **neuroblastoma**. - Its uptake mechanism targets cells of neuroectodermal origin, which is distinct from the iodine uptake mechanism of thyroid cells.
Question 4: Radiation-induced necrosis can be diagnosed by:
- A. MRI
- B. CT
- C. PET
- D. Biopsy (Correct Answer)
Explanation: ***Biopsy*** - A **biopsy** is the definitive diagnostic method for radiation-induced necrosis, allowing for histological examination of tissue to confirm necrosis and rule out residual or recurrent tumor. [1], [2] - It provides a direct view of cellular changes, identifying **necrosis, atypical cells**, and ruling out **malignancy**. *MRI* - While **MRI** can show structural changes indicative of necrosis (e.g., mass effect, edema), it often cannot definitively differentiate between **radiation necrosis** and **tumor recurrence.** [2] - It often shows **T1 hypointensity** and **T2 hyperintensity**, but these findings are not specific. *CT* - **CT scans** are useful for detecting gross changes like **mass effect** and **edema** but have limited sensitivity for distinguishing necrosis from tumor recurrence. - It may show **low-density lesions** but lacks the resolution and specificity for precise diagnosis. *PET* - **PET scans** measure metabolic activity and can help distinguish between **tumor recurrence** (high uptake) and **radiation necrosis** (low uptake) in some cases. - However, false positives can occur, as some inflammatory processes in necrosis can also show increased uptake, making it **less definitive** than a biopsy. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Central Nervous System, pp. 1307-1308. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 340-341.
Question 5: Which radioisotope is PRIMARILY used for detecting acute myocardial infarction rather than assessing myocardial perfusion?
- A. Thallium 201
- B. Tc-99m Sestamibi
- C. Tc-99m Pyrophosphate (Correct Answer)
- D. 18-FDG PET
Explanation: ***Tc-99m Pyrophosphate*** - This radioisotope binds to **calcium deposits** in infarcted myocardial tissue, which accumulate 12-24 hours after injury. - It is particularly useful for detecting **acute myocardial infarction** (hot spot imaging) when cardiac biomarkers may be unreliable or in cases of delayed presentation. - Shows positive uptake in necrotic tissue, making it a "positive" or "hot spot" agent for acute MI. *Thallium 201* - **Thallium 201** is a potassium analog that is actively transported into viable myocardial cells. - It is primarily used for assessing **myocardial perfusion** and viability, showing areas of reduced blood flow or scar tissue. - Acts as a "cold spot" agent - infarcted areas show reduced uptake. *Tc-99m Sestamibi* - **Tc-99m Sestamibi** is a commonly used tracer for **myocardial perfusion imaging (SPECT)**, indicating blood flow to the heart muscle. - It accumulates in viable myocardial cells in proportion to blood flow and is not specific for acute myocardial necrosis. - Used primarily for stress testing and perfusion assessment, not acute infarct detection. *18-FDG PET* - **18-FDG PET** (Fluorodeoxyglucose Positron Emission Tomography) primarily measures **glucose metabolism** in the myocardium. - It is predominantly used to assess **myocardial viability** in areas of hibernating myocardium rather than acute infarction. - Helps distinguish viable but ischemic tissue from scar tissue.
Question 6: Radiopharmaceutical used for phagocyte study scan:
- A. MDP scan
- B. Thallium 201
- C. Technetium pertechnetate scan
- D. Sulfur colloid scan (Correct Answer)
Explanation: ***Sulfur colloid scan*** - **Sulfur colloid** is readily phagocytosed by **Kupffer cells** in the liver and spleen, making it useful for evaluating their function. - This scan allows for the assessment of the **reticuloendothelial system's phagocytic activity**, which involves various phagocytes. *MDP scan* - **MDP (methylene diphosphonate)** is used primarily for **bone scans** to detect bone abnormalities, infections, or tumors. - It accumulates in areas of increased **osteoblastic activity**, not phagocytic activity. *Thallium 201* - **Thallium 201** is largely used in **myocardial perfusion imaging** to assess blood flow to the heart muscle. - It acts as a potassium analog and is taken up by viable myocardial cells, not phagocytes. *Technetium pertechnetate scan* - **Technetium pertechnetate** is commonly used for **thyroid scans**, Meckel's diverticulum scans, and brain scans. - It accumulates in glandular tissues with active transport mechanisms involving iodide, and is not involved in phagocyte studies.
Question 7: Technetium-99m methylene diphosphonate is structurally similar to
- A. Sodium bicarbonate
- B. Phosphorus
- C. Calcium phosphate (Correct Answer)
- D. Magnesium sulfate
Explanation: ***Calcium phosphate*** - **Technetium-99m methylene diphosphonate (Tc-99m MDP)** is used in bone scans because it structurally mimics **calcium phosphate**, the primary mineral component of bone. - This structural similarity allows Tc-99m MDP to be incorporated into the **hydroxyapatite crystals** present in bone, making it an effective tracer for skeletal imaging. *Sodium bicarbonate* - **Sodium bicarbonate** is a basic salt with a different chemical structure, primarily involved in maintaining pH balance in the body, not bone matrix. - It does not contain phosphate groups or the specific molecular configuration needed to bind to **hydroxyapatite crystals**. *Phosphorus* - While **phosphorus** is a component of calcium phosphate, free phosphorus (as an element) is not structurally similar to Tc-99m MDP. - Tc-99m MDP is a diphosphonate, a complex molecule where the phosphonate groups are critical for bone binding, not just elemental phosphorus. *Magnesium sulfate* - **Magnesium sulfate** is an inorganic salt used for various medical purposes, but it does not have the diphosphonate structure or the affinity for bone mineralization sites that Tc-99m MDP possesses. - Its chemical structure is fundamentally different from that of bone matrix components, preventing its use as a bone imaging agent.
Question 8: A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?
- A. 64Cu for longer imaging window despite inferior image quality
- B. 64Cu because shorter positron range improves resolution
- C. 18F for better spatial resolution despite requiring on-site cyclotron (Correct Answer)
- D. 18F because longer half-life allows delayed imaging
Explanation: ***18F for better spatial resolution despite requiring on-site cyclotron*** - **18F** has a shorter **positron range** compared to **64Cu**, which minimizes the distance the positron travels before annihilation, leading to superior **spatial resolution**. - While it necessitates proximity to a **cyclotron** due to a 110-minute half-life, this timeframe is sufficient for most **hypoxia imaging** tracers to reach a high **target-to-background ratio**. *64Cu for longer imaging window despite inferior image quality* - **64Cu** provides a longer imaging window due to its **12.7-hour half-life**, but its longer **positron range** leads to increased **blurring** and poorer resolution. - For diagnostic **tumor hypoxia**, the extra-long window is often unnecessary and leads to a higher **absorbed radiation dose** for the patient. *64Cu because shorter positron range improves resolution* - This statement is factually incorrect as **64Cu** actually has a significantly longer **effective positron range** than **18F**. - Higher **energy positrons** travel further in tissue, which degrades the **image quality** by misplacing the site of annihilation relative to the source. *18F because longer half-life allows delayed imaging* - This is incorrect as **18F** has a much shorter half-life (**110 minutes**) compared to the **12.7 hours** of **64Cu**. - The shorter half-life of **18F** prevents very late delayed imaging but helps in keeping the total **patient radiation exposure** lower.
Question 9: In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?
- A. 18F-PSMA with 4 hour delayed imaging
- B. 68Ga-PSMA with 3 hour uptake time without furosemide
- C. 68Ga-PSMA with 1 hour uptake time and furosemide administration (Correct Answer)
- D. 18F-PSMA with 30 minutes uptake time and forced hydration
Explanation: ***68Ga-PSMA with 1 hour uptake time and furosemide administration*** - An **uptake time of 60 minutes** is the standard for **68Ga-PSMA**, providing an optimal **target-to-background ratio** (TBR) while maintaining efficient clinical workflow. - The administration of **furosemide** (a loop diuretic) promotes **urinary washout** of the tracer, reducing interfering **bladder activity** and lowering the radiation dose to the urinary tract. *18F-PSMA with 4 hour delayed imaging* - While **18F-labeled tracers** have a longer half-life, a 4-hour delay is excessive and leads to significant **decay of activity**, potentially requiring higher initial doses and increasing **radiation exposure**. - Such long delays are not practical for routine clinical protocols and do not provide a significant clinical advantage over standard 1-2 hour imaging for most **PSMA** ligands. *68Ga-PSMA with 3 hour uptake time without furosemide* - **68Ga** has a short physical half-life (68 minutes), so a 3-hour wait significantly reduces the **count rate**, leading to poor **image quality** due to increased noise. - Omitting **furosemide** results in high tracer concentration in the **bladder**, which can obscure local recurrence in the **prostate bed** or nearby pelvic lymph nodes via **halo artifacts**. *18F-PSMA with 30 minutes uptake time and forced hydration* - A **30-minute uptake time** is generally insufficient for optimal **tracer internalization** into prostate cancer cells, resulting in a lower **tumor-to-background ratio**. - Although **forced hydration** helps, it is less effective than **furosemide** at rapidly clearing the high-intensity tracer from the **distal ureters** and bladder during the peak imaging window.
Question 10: A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?
- A. Progressive disease requiring treatment escalation
- B. Treatment-induced necrosis with favorable prognosis (Correct Answer)
- C. Flare phenomenon indicating treatment response
- D. Infection complicating the metastasis
Explanation: ***Treatment-induced necrosis with favorable prognosis*** - A decrease in **SUVmax** indicates a reduction in **metabolic activity** and viable tumor cells, even if the physical dimensions of the lesion increase. - The increase in size is often due to **necrosis, edema, or inflammation** following successful therapy, representing a favorable response to treatment rather than failure. *Progressive disease requiring treatment escalation* - Progressive disease typically presents with an **increase in both size and SUVmax**, reflecting active metabolic growth of the tumor. - Relying solely on **CT size measurements** (like RECIST criteria) can be misleading when PET shows a significant drop in **glucose metabolism**. *Flare phenomenon indicating treatment response* - The **flare phenomenon** usually refers to a transient *increase* in tracer uptake (SUVmax) shortly after starting treatment (e.g., bone flare in breast cancer patients). - In this scenario, the activity **decreased over 3 months**, which is more consistent with a sustained metabolic response than a metabolic flare. *Infection complicating the metastasis* - An active infection or inflammatory process would typically lead to an **increase in SUVmax** due to high metabolic activity in activated white blood cells. - There is no clinical information provided to suggest systemic **fever or local infection**, and the metabolic trend (decreasing SUV) contradicts an inflammatory spike.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free